CRMO- CLINICAL RESEARCH MANAGEMENT OFFICE
CRMO-临床研究管理办公室
基本信息
- 批准号:8375790
- 负责人:
- 金额:$ 32.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdministratorAdverse eventAmendmentBioinformaticsBiostatistics Shared ResourceBudgetsCancer CenterCancer Center Support GrantClinicalClinical DataClinical ResearchClinical Research AssociateClinical TrialsClinical Trials Informatics SystemCommunicationConduct Clinical TrialsConsent FormsDataDatabasesDiagnostic and Statistical ManualDistrict of ColumbiaDocumentationEnsureFundingGoalsGrantGuidelinesHeadHerbert Irving Comprehensive Cancer CenterIndustryInformaticsInformation SystemsInstitutional Review BoardsInternetMalignant NeoplasmsMediationMedical centerModelingMonitorNursing ResearchOffice ManagementOperations ResearchPeer ReviewPeer Review GrantsPharmaceutical PreparationsProceduresProcessProtocols documentationQuality ControlReactionReportingResearchResearch ActivityResearch InfrastructureResearch PersonnelResearch ProposalsResource SharingSouthwest Oncology GroupSupervisionTrainingUniversitiesWorkdata managementdrug developmentexperiencememberoperationquality assuranceweb site
项目摘要
The Clinical Research Management Office (CRMO) provides infrastructure for the conduct of clinical
research at the HICCC. The functions of the CRMO include:
¿ Facilitating the conduct of clinical research by maintaining the administrative and trial management
operations,
¿ Working closely with Bioinformatics to ensure the optimal operation of clinical information systems
and databases, and
¿ Providing an interface with regulatory and sponsoring agencies.
To accomplish these goals, the CRMO has four offices, Research Nursing, Data Management, Research
Operations and Regulatory Management, and Data Applications. Experienced senior managers head each
of the four offices and the heads of the first three report to the Administrator for Research Operations. The
Offices of Research Nursing and of Data Management are responsible for the assignment, supervision,
and training of 12 research nurses and 28 data managers and clinical research associates who staff
HICCC clinical trials. The Office of Data Management is also responsible for audit compliance and quality
assurance. The office of Research Operations and Regulatory Management, with a supervisor and a
staff of 7, maintains files on each protocol submitted to the CRMO, submits protocols, amendments, annual
reviews and adverse drug reaction reports to the IRB and PRMC and maintains current copies of open
protocols on a password protected website for investigators and staff. The office is also responsible for
oversight of quality control of the CRMO and implementation of new procedures. The Data Applications
Group reports jointly to the Director of the CRMO and to the Director of Bioinformatics and handles the
informatics that includes the implementation and management of Velos, a clinical trials informatics system
compatible with CaBIG. The CRMO works closely with the Protocol Review and Monitoring Committee
(PRMC), with investigators, and with the Biostatistics Shared Resource to bring efficient, seamless and
responsible clinical trials management to the Cancer Center. The projected operating budget of the CRMO
is $517,204, of which we are requesting $249,084 from the CCSG.
临床研究管理办公室(CRMO)为开展临床研究提供基础设施。
HICCC的研究。CRMO的职能包括:
通过维持行政和试验管理,促进临床研究的开展
操作,
与生物信息学密切合作,确保临床信息系统的最佳运行
数据库,以及
提供与监管和赞助机构的接口。
为了实现这些目标,CRMO有四个办公室,研究护理,数据管理,研究
运营和监管管理以及数据应用。经验丰富的高级管理人员领导每个
四个办公室的负责人和前三个办公室的负责人向研究业务署长报告。的
研究护理办公室和数据管理办公室负责分配、监督,
培训了12名研究护士和28名数据管理员和临床研究助理,
CIMCC临床试验。数据管理办公室还负责审计合规性和质量
保证。研究运营和监管管理办公室,有一名主管和一名
7名工作人员,维护提交给CRMO的每份方案的档案,提交方案,修正案,年度
审查和药物不良反应报告给IRB和PRMC,
为调查人员和工作人员在密码保护的网站上发布了一份协议。该办公室还负责
监督CRMO的质量控制和新程序的实施。数据应用
该小组共同向CRMO主任和生物信息学主任报告,
信息学,包括实施和管理Velos,一个临床试验信息学系统
与CaBIG兼容。CRMO与议定书审查和监测委员会密切合作
(PRMC),与研究者,并与生物统计共享资源,使高效,无缝,
负责癌症中心的临床试验管理。CRMO的预计业务预算
是517,204美元,其中我们要求CCSG提供249,084美元。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edward P Gelmann其他文献
Edward P Gelmann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edward P Gelmann', 18)}}的其他基金
Role of the DNA Damage Response in Prostate Cancer Initiation
DNA 损伤反应在前列腺癌发生中的作用
- 批准号:
8555289 - 财政年份:2011
- 资助金额:
$ 32.79万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 32.79万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 32.79万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 32.79万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 32.79万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 32.79万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 32.79万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 32.79万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 32.79万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 32.79万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 32.79万 - 项目类别:














{{item.name}}会员




